PPT-Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Author : hadly | Published Date : 2023-12-30

Huang SS Labus BJ Samuel MC Wan DT Reingold AL Antibiotic Resistance Patterns of Bacterial Isolates from Blood in San Francisco County California 19961999 Emerg

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 4 Figure 4. Yearly perce..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,: Transcript

Huang SS Labus BJ Samuel MC Wan DT Reingold AL Antibiotic Resistance Patterns of Bacterial Isolates from Blood in San Francisco County California 19961999 Emerg Infect Dis 200282195201 httpsdoiorg103201eid0802010102. Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M, et al. Ciprofloxacin-Resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis. 2007;13(10):1614-1616. https://doi.org/10.3201/eid1310.060820. Bansal V, Metzner KJ, Niederöst B, Leemann C, Böni J, Günthard HF, et al. Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1–infected Eritrean Immigrant. Emerg Infect Dis. 2011;17(10):1966-1968. https://doi.org/10.3201/eid1710.110592. King CH, Muchiri EM, Ouma JH. Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis. 2000;6(6):585-594. https://doi.org/10.3201/eid0606.000606. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current Epidemiology of Pneumocystis Pneumonia. Emerg Infect Dis. 2004;10(10):1713-1720. https://doi.org/10.3201/eid1010.030985. Doublet B, Lailler R, Meunier D, Brisabois A, Boyd D, Mulvey MR, et al. Variant Salmonella Genomic Island 1 Antibiotic Resistance Gene Cluster in Salmonella enterica Serovar Albany. Emerg Infect Dis. 2003;9(5):585-591. https://doi.org/10.3201/eid0905.020609. Marcus PI, Girshick T, van der Heide L, Sekellick MJ. Super-Sentinel Chickens and Detection of Low-Pathogenicity Influenza Virus. Emerg Infect Dis. 2007;13(10):1608-1610. https://doi.org/10.3201/eid1310.061552. with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms. Mariana Castanheira, Jill Lindley, . Brieanna. M. Roth, Timothy B. Doyle, Andrew P. Davis, . Helio. S. . Dietz K, Raddatz G, Wallis J, Müller N, Zerr I, Duerr H, et al. Blood Transfusion and Spread of Variant Creutzfeldt-Jakob Disease. Emerg Infect Dis. 2007;13(1):89. https://doi.org/10.3201/eid1301.060396. Andraševiæ AT, Tambiæ T, Kaleniæ S, Jankoviæ V. Surveillance for Antimicrobial Resistance in Croatia. Emerg Infect Dis. 2002;8(1):14-18. https://doi.org/10.3201/eid0801.010143. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial Drug Use and Resistance in Europe. Emerg Infect Dis. 2008;14(11):1722-1730. https://doi.org/10.3201/eid1411.070467. Kirschner DE, Webb G. Resistance, Remission, and Qualitative Differences in HIV Chemotherapy. Emerg Infect Dis. 1997;3(3):273-283. https://doi.org/10.3201/eid0303.970303. Salzberg SL, Kingsford C, Cattoli G, Spiro DJ, Janies DA, Aly MM, et al. Genome Analysis Linking Recent European and African Influenza (H5N1) Viruses. Emerg Infect Dis. 2007;13(5):713. https://doi.org/10.3201/eid1305.070013. Shah N, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, et al. Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa. Emerg Infect Dis. 2011;17(3):510-513. https://doi.org/10.3201/eid1703.101363. Pottumarthy S, Moland ES, Juretschko S, Swanzy SR, Thomson KS, Fritsche TR. NmcA Carbapenem-hydrolyzing Enzyme in Enterobacter cloacae in North America. Emerg Infect Dis. 2003;9(8):999-1002. https://doi.org/10.3201/eid0908.030096.

Download Document

Here is the link to download the presentation.
"Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4. a. Hardy-Weinberg equilibrium analysis of the increase in

PPT-Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Presentation Embed Code

Download Presentation

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,: Transcript

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4. a. Hardy-Weinberg equilibrium analysis of the increase in

Figure 1 Figure 1. Yearly opportunistic infection rates per 1,000 person-years,

Figure 1 Figure 1. Genetic organization of the antibiotic resistance gene cluster

Figure 2 Figure 2. Seroconversion in sentinel specific-pathogen-free white leghorns

In Vitro Selection of Enterobacter cloacae

Figure 3 Figure 3. The yearly incidence of deaths for an incubation period of

Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 2 Figure 2. Proportion of penicillin-nonsusceptible Streptococcus pneumoniae

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 1 Figure 1. Phylogenetic tree of hemagglutinin (HA) segments from 36 avian

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Figure 2 Figure 2. Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL)

PPT-Figure 4 Figure 4.&nbsp;Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Presentation Embed Code

Download Presentation

Figure 4 Figure 4.&nbsp;Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,: Transcript

Figure Figure.&nbsp;Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4.&nbsp;a. Hardy-Weinberg equilibrium analysis of the increase in

Figure 1 Figure 1.&nbsp;Yearly opportunistic infection rates per 1,000 person-years,

Figure 1 Figure 1.&nbsp;Genetic organization of the antibiotic resistance gene cluster

Figure 2 Figure 2.&nbsp;Seroconversion in sentinel specific-pathogen-free white leghorns

In Vitro Selection of Enterobacter cloacae

Figure 3 Figure 3.&nbsp;The yearly incidence of deaths for an incubation period of

Figure 3 Figure 3.&nbsp;Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 2 Figure 2.&nbsp;Proportion of penicillin-nonsusceptible Streptococcus pneumoniae

Figure 5 Figure 5.&nbsp;5a simulates combined drug treatment data reported for a patient

Figure 1 Figure 1.&nbsp;Phylogenetic tree of hemagglutinin (HA) segments from 36 avian

Figure 2 Figure 2.&nbsp;Determination of prevalence of tuberculosis (TB) and drug

Figure 2 Figure 2.&nbsp;Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL)

PPT-Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,: Transcript

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure 4 Figure 4. a. Hardy-Weinberg equilibrium analysis of the increase in

Figure 1 Figure 1. Yearly opportunistic infection rates per 1,000 person-years,

Figure 1 Figure 1. Genetic organization of the antibiotic resistance gene cluster

Figure 2 Figure 2. Seroconversion in sentinel specific-pathogen-free white leghorns

Figure 3 Figure 3. The yearly incidence of deaths for an incubation period of

Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 2 Figure 2. Proportion of penicillin-nonsusceptible Streptococcus pneumoniae

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 1 Figure 1. Phylogenetic tree of hemagglutinin (HA) segments from 36 avian

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Figure 2 Figure 2. Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL)